Ani Pharmaceuticals (ANIP) Change in Accured Expenses (2010 - 2018)

Ani Pharmaceuticals has disclosed Change in Accured Expenses across 9 years of filings, most recently posting $1.0 million for Q3 2018.

• In Q3 2018, Change in Accured Expenses fell 43.14% year-over-year to $1.0 million; the TTM figure through Sep 2018 stood at $174000.0 (up 74.0% YoY), while the FY2017 annual figure was $644000.0, down 31.49% from the prior year.
• Change in Accured Expenses came in at $1.0 million for Q3 2018 at Ani Pharmaceuticals, up from -$749000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $1.8 million in Q3 2017 to a low of -$1.9 million in Q4 2015.
• Average Change in Accured Expenses over 5 years is $171473.7, with a median of $143000.0 recorded in 2014.
• Year-over-year, Change in Accured Expenses sank 523.08% in 2015 and soared 45125.0% in 2017.
• Over 5 years, Change in Accured Expenses stood at -$630000.0 in 2014, then slumped by 198.57% to -$1.9 million in 2015, then grew by 8.88% to -$1.7 million in 2016, then surged by 31.74% to -$1.2 million in 2017, then surged by 187.52% to $1.0 million in 2018.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were $1.0 million in Q3 2018, -$749000.0 in Q2 2018, and $1.1 million in Q1 2018.